Male breast cancer: Specific biological characteristics and survival in a Portuguese cohort

• Published in: Molecular and clinical oncology 2019-06, Vol.10 (6), p.644-654
• Main Authors: André, Saudade, Pereira, Teresa, Silva, Fernanda, Machado, Patrícia, Vaz, Fátima, Aparício, Mariana, Silva, Giovani L, Pinto, António E
• Format: Article
• Language: English
• Subjects: Antigens; BRCA mutations; Breast cancer; Cancer metastasis; Cancer therapies; Deoxyribonucleic acid; Disease; DNA; DNA repair; Family medical history; Females; Fluorescence; Gene expression; Gene mutation; Genetic aspects; Immunohistochemistry; Males; Mammography; Medical research; Mens health; Metastasis; Mortality; Mutation; Oncology; Operating systems (Software); Patients; Phenols (Class of compounds); Progesterone; Regression analysis; Sex hormones; Tumors; Tyrosine; Women
• ISSN: 2049-9450; 2049-9469
• DOI: 10.3892/mco.2019.1841

Male breast cancer (BC) represents an individual subtype of BC, with therapeutic procedures based on female BC therapy results. The present study evaluated the parameters currently used for the characterization and therapy of male BC, and their association with disease-free (DFS) and overall survival (OS), aiming to obtain a comprehensive basis to improve the personalized care of male BC. A total of 196 patients from March 1970 to March 2018 (mean follow-up, 84.9 months) were profiled, using clinicopathological review, molecular assessment [BRCA1/2, DNA repair associated (BRCA1/2) status, immunohistochemistry, fluorescence hybridization and DNA flow cytometry] and Cox regression statistical analysis. The median age of patients was 66.5 years. At presentation, 39.2% of patients with invasive carcinomas were in anatomic stage (AS) I. Patients exhibited primarily invasive carcinomas of no special type, histological grade 2, estrogen receptor α-(ERα) and progesterone receptor (PR)-positive, receptor tyrosine kinase erbB-2-negative, high Ki-67, Luminal B-like and aneuploid tumors. A total of 13 of the 44 (29.5%) BRCA-evaluated patients exhibited BRCA2 mutations, significantly associated with family history (FH), bilaterality, high Ki-67 expression, absence of PR and Luminal B-like tumors. Bilaterality was associated with the occurrence of non-breast primary neoplasms (NBPN). The 5 and 10-year DFS rates, excluding patients with distant metastasis, NBPN and carcinomas (n=145) were 65.9 and 58.2%, respectively, and the 5 and 10-year OS rates were 77.5 and 59.2%, respectively. In the univariate analysis, Luminal B-like subtype, BRCA2 mutations, high Ki-67 expression, and AS II and III were significantly associated with shorter DFS and OS. In addition, age >70 years was associated with low OS. In the multivariate analysis, FH, AS II and III, and Luminal B-like subtypes were associated with poorer OS. In conclusion, the data from the present study emphasize the high incidence of BRCA2 mutation in male BC, and its association with FH, bilaterality, high Ki-67 expression, negative PR expression and Luminal B-like subtypes, and with shorter DFS and OS in univariate analysis.